

OUR CLINICAL TRIALS

Advancing oncology at the speed of life™




AMGEN®

Oncology




MULTIPLE MYELOMA

	AMG 701 HLE BiTE® platform (HLE BiTE® molecule targeting BCMA)
NCT: 03287908 Amgen ID*: 20170122	Status
First-in-Human Study of AMG 701 in Multiple Myeloma	Phase 1 (R)
	Carfilzomib† Small molecule (proteasome inhibitor)
NCT: 03091127 Amgen ID*: 20150262	Status
Real-world Use of Carfilzomib Among Patients With Relapsed MM in Europe	Phase Observational (C)
NCT: 03512353 Amgen ID*: 20170596	Status
A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers	Phase 2 (C)
NCT: 03859427 Amgen ID*: 20180015	Status
Study of Once-Weekly vs Twice Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)	Phase 3 (R)
NCT: 03158688 Amgen ID*: 20160275	Status
Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (CANDOR)	Phase 3 (A)
NCT: 04191616 Amgen ID*: 20180117	Status
Study of Carfilzomib Plus Pomalidomide and Dexamethasone in Patients With First or Second Relapse of Multiple Myeloma	Phase 2 (N)


LEUKEMIA ACUTE MYELOID LEUKEMIA

	AMG 330 BiTE® platform (BiTE® molecule targeting CD33)
NCT: 02520427 Amgen ID*: 20120252	Status
First-in-Human Study of AMG 330 in Adult Patients With Relapsed or Refractory AML	Phase 1 (R)
	AMG 673 HLE BiTE® platform (HLE BiTE® molecule targeting CD33)
NCT: 03224819 Amgen ID*: 20160377	Status
First-in-Human Study of AMG 673 in Adult Patients With Relapsed or Refractory AML	Phase 1 (R)
	AMG 427 HLE BiTE® platform (HLE BiTE® molecule targeting [FLT3] antigen)
NCT: 03541369 Amgen ID*: 20170528	Status
First-in-Human Study of AMG 427 in Patients With Relapsed/Refractory AML	Phase 1 (R)

LEUKEMIA ACUTE MYELOID LEUKEMIA (continued)


	AMG 176 Small molecule (Intravenous MCL-1 inhibitor)
NCT: 02675452 Amgen ID*: 20150161	Status
First-in-Human Study of AMG 176 in Relapsed or Refractory AML	Phase 1 (A)
	AMG 397 Small molecule (Oral MCL-1 inhibitor)
NCT: 03465540 Amgen ID*: 20170173	Status
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Patients With Hematologic Malignancies	Phase 1 (A)
	AMG 553 Anti-FLT3 CAR T
NCT: 03904069 Amgen ID*: 20180091	Status
First in Human Study of AMG 553 in Patients With Relapsed or Refractory Acute Myeloid Leukemia	Phase 1 (N)

LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA


	Blinatumomab BiTE® platform (BiTE® molecule targeting CD19)
NCT: 02412306 Amgen ID*: 20130265	Status
Study of Blinatumomab in Japanese Patients With Relapsed or Refractory B-Precursor ALL	Phase 1b/2 (C)
NCT: 02393859 Amgen ID*: 20120215	Status
Blinatumomab vs Standard Chemotherapy in Pediatric Patients With High Risk First Relapse B-Precursor ALL	Phase 3 (A)
NCT: 03476239 Amgen ID*: 20130316	Status
Study of Blinatumomab in Chinese Adult Patients With Relapsed or Refractory B-precursor ALL	Phase 3 (A)
NCT: 02783651 Amgen ID*: 20150253	Status
Observational Study of Patients With Philadelphia Chromosome-Negative Relapsed or Refractory ALL in the US	Phase Observational (C)
NCT: 02187354 Amgen ID*: 20130320	Status
Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Patients With Relapsed or Refractory B-Precursor ALL (RIALTO)	No longer available Phase 4
NCT: 03117621 Amgen ID*: 20150136	Status
Observational Study of Blinatumomab	Phase 4 (R)


(N) Not yet recruiting (R) Active, recruiting (A) Active, not recruiting (C) Completed, pending results


LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA (continued)

	Carfilzomib[†] Small molecule (proteasome inhibitor)		
NCT: 02303821	Amgen ID*: CFZ008	Status	
Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory ALL	(R)		Phase 1b


LYMPHOMA NON-HODGKIN LYMPHOMA

	ABP 798[‡] Monoclonal antibody (rituximab biosimilar)		
NCT: 02747043	Amgen ID*: 20130109	Status	
Efficacy and Safety Study of ABP 798 Compared With Rituximab in Treating Non-Hodgkin Lymphoma (JASMINE)	(C)		Phase 3


	AMG 562 HLE BiTE [®] Platform (HLE BiTE [®] molecule targeting CD19)		
NCT: 03571828	Amgen ID*: 20170533	Status	
First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma	(R)		Phase 1

	Blinatumomab BiTE [®] platform (BiTE [®] molecule targeting CD19)		
NCT: 02961881	Amgen ID*: 20140286	Status	
Safety and PK of Subcutaneous Blinatumomab in Relapsed or Refractory Indolent NHL	(R)		Phase 1b
NCT: 03340766	Amgen ID*: 20150290	Status	
Efficacy and Safety of Blinatumomab in Combination With Pembrolizumab in Adult Patients With Relapsed or Refractory DLBCL (KEYNOTE-348)	(A)		Phase 1b
NCT: 03023878	Amgen ID*: 20150288	Status	
Efficacy and Safety of Blinatumomab in Patients With Newly Diagnosed High-Risk DLBCL	(C)		Phase 2
NCT: 02910063	Amgen ID*: 20150292	Status	
Efficacy and Safety of Blinatumomab in Patients With Relapsed or Refractory Aggressive B-Cell NHL	(C)		Phase 2


OTHER PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

	ABP 959[‡] Monoclonal antibody (eculizumab biosimilar)		
NCT: 03818607	Amgen ID*: 20150168	Status	
Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)	(R)		Phase 3



OTHER CHRONIC GRAFT VERSUS HOST DISEASE

	AMG 592 Protein/Peptibody (IL-2 mutein)		
NCT: 03422627	Amgen ID*: 20160283	Status	
Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Patients With Steroid Refractory Chronic Graft Versus Host Disease	(R)		Phase 1b/2



OTHER IMMUNE THROMBOCYTOPENIA

	Romiplostim Protein/Peptibody (thrombopoiesis stimulator)		
NCT: 02279173	Amgen ID*: 20101221	Status	
Single-Arm, Open-Label, Long-Term Study of Romiplostim in Thrombocytopenic Pediatric Patients With ITP	(C)		Phase 3



LUNG CANCER NON SMALL CELL LUNG CANCER


	Sotorasib (proposed INN for AMG 510) Small molecule (KRAS ^{G12C} inhibitor)		
NCT: 03600883 Amgen ID*: 20170543	Status		
CodeBreak 100: Open-Label Study Evaluating AMG 510 Monotherapy and in Combination Therapy With Anti-PD-1/L1 in NSCLC With <i>KRAS G12C</i> Mutation	Ⓡ		Phase 1/2
NCT: 04185883 Amgen ID*: 20190135	Status		
CodeBreak 101: Open-Label Study Evaluating AMG 510 Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With <i>KRAS G12C</i> Mutation	Ⓡ		Phase 1b
NCT: 04303780 Amgen ID*: 20190009	Status		
CodeBreak 200: A Phase 3 Study to Compare Sotorasib (proposed INN for AMG 510) With Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC With <i>KRAS G12C</i> Mutation	Ⓡ		Phase 3
	Romiplostim Protein/Peptibody (thrombopoiesis stimulator)		
NCT: 03937154 Amgen ID*: 20170770	Status		
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia in Patients With Non Small Cell Lung, Ovarian or Breast cancer	Ⓡ		Phase 3

LUNG CANCER SMALL CELL LUNG CANCER



	AMG 119 CAR T-Cell therapy (anti-DLL3 CAR-T)		
NCT: 03392064 Amgen ID*: 20170124	Status		
First-in-Human Study of AMG 119 to Evaluate the Safety, Tolerability and Efficacy in Patients With RR SCLC	Ⓐ		Phase 1
	AMG 757 HLE BiTE [®] platform (HLE BiTE [®] molecule targeting DLL3)		
NCT: 03319940 Amgen ID*: 20160323	Status		
First-in-Human Study Evaluating AMG 757 Monotherapy and in Combination With Anti-PD1 Therapy in SCLC	Ⓡ		Phase 1

PROSTATE CANCER


	AMG 160 HLE BiTE [®] platform (HLE BiTE [®] molecule targeting PSMA)		
NCT: 03792841 Amgen ID*: 20180101	Status		
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Patients With mCRPC	Ⓡ		Phase 1
	AMG 212 BiTE [®] platform (BiTE [®] molecule targeting PSMA)		
NCT: 01723475 Amgen ID*: 15590	Status		
Phase 1 Study of Pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T-cell Engager (BiTE [®]) Immunotherapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Ⓒ		Phase 1

	AMG 509 XmAb [®] Platform (XmAb [®] targeting STEAP1)		
NCT: 04221542 Amgen ID*: 20180146	Status		
Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Ⓡ		Phase 1


GASTRIC & GASTROESOPHAGEAL JUNCTION CANCER

	AMG 910 BiTE [®] platform (BiTE [®] molecule targeting CLDN18.2)		
NCT: 04260191 Amgen ID*: 20180292	Status		
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma	Ⓝ		Phase 1
	AMG 199 HLE BiTE [®] Platform (HLE BiTE [®] molecule targeting MUC17)		
NCT: 04117958 Amgen ID*: 20180290	Status		
A Phase 1 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer	Ⓡ		Phase 1


GASTROINTESTINAL OR COLORECTAL CANCER

	Romiplostim Protein/Peptibody (thrombopoiesis stimulator)		
NCT: 03362177 Amgen ID*: 20140346	Status		
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia in Patients With Gastrointestinal or Colorectal Cancer	Ⓡ		Phase 3

GIANT CELL TUMORS OF THE BONE


	Denosumab Monoclonal antibody (RANK-ligand inhibitor)		
NCT: 03301857 Amgen ID*: 20140114	Status		
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004	Ⓐ		Phase 4

GLIOBLASTOMA / MALIGNANT GLIOMA

	AMG 596 BiTE [®] platform (BiTE [®] molecule targeting EGFRvIII)		
NCT: 03296696 Amgen ID*: 20160132	Status		
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 monotherapy or in combination With AMG 404 in Adult Patients With EGFRvIII positive Glioblastoma or Malignant Glioma	Ⓡ		Phase 1

Ⓝ Not yet recruiting Ⓡ Active, recruiting Ⓐ Active, not recruiting Ⓒ Completed, pending results

SOLID TUMORS WITH *KRAS G12C* MUTATION

	Sotorasib (proposed INN for AMG 510) Small molecule (<i>KRAS</i> ^{G12C} inhibitor)		
NCT: 03600883 Amgen ID*: 20170543	Status		Phase 1/2
CodeBreak 100: Open-Label Study Evaluating AMG 510 Monotherapy in Advanced Solid Tumors With <i>KRAS G12C</i> Mutation	Ⓡ		
NCT: 04185883 Amgen ID*: 20190135	Status		Phase 1b
CodeBreak 101: Open-Label Study Evaluating AMG 510 Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With <i>KRAS G12C</i> Mutation	Ⓡ		

VARIOUS SOLID TUMORS

	AMG 256 Bi-functional fusion protein (Targeted IL-21 receptor agonist)		
NCT: 04362748 Amgen ID*: 20180144	Status		Phase 1
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	Ⓝ		
	AMG 506[#] (also known as MPO310) DARPin [®] protein targeting FAP x 4-1BB		
NCT: 04049903 Study ID*: MPO310-CP101	Status		Phase 1
A First-In-Human, Single-Arm, Multi-Center, Open-Label, Repeated-Dose, Dose-Escalation Study of MPO310 in Patients With Advanced Solid Tumors	Ⓡ		
	AMG 404 Monoclonal antibody (Anti-PD1)		
NCT: 03853109 Amgen ID*: 20180143	Status		Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, in Patients With Advanced Solid Tumors	Ⓡ		
	Pegfilgrastim Protein (G-CSF)		
EU PAS**: 24626 Amgen ID*: 20170758	Status		Phase Observational
Prospective Observational Study to Estimate Incidence of Febrile Neutropenia in High Risk Patients With Non-myeloid Malignancies Receiving Pegfilgrastim OBI (Onbody Injector) or Physician Choice for Febrile Neutropenia Prophylaxis	Ⓡ		
	Talimogene laherparepvec^{††} Oncolytic immunotherapy (oncolytic viral therapy)		
NCT: 02756845 Amgen ID*: 20110261	Status		Phase 1
Study of Talimogene Laherparepvec in Children With Advanced Non-CNS Tumors	Ⓡ		
NCT: 03064763 Amgen ID*: 20140270	Status		Phase 1
Study to Evaluate the Safety/Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma	Ⓐ		

NCT: 02626000 Amgen ID*: 20130232	Status		Phase 1b
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232/KEYNOTE-137)	Ⓐ		
NCT: 02509507 Amgen ID*: 20140318	Status		Phase 1b
Safety Study of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318)	Ⓡ		
NCT: 03256344 Amgen ID*: 20140299	Status		Phase 1b
Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases	Ⓡ		
NCT: 01740297 Amgen ID*: 20110264	Status		Phase 1b/2
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma	Ⓐ		
NCT: 04068181 Amgen ID*: 20180115	Status		Phase 2
T-VEC With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)	Ⓡ		
NCT: 02211131 Amgen ID*: 20110266	Status		Phase 2
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma	Ⓐ		
NCT: 02366195 Amgen ID*: 20120325	Status		Phase 2
Single-Arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma	Ⓐ		
NCT: 02263508 Amgen ID*: 20110265	Status		Phase 3
Pembrolizumab With or Without Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)	Ⓐ		
NCT: 02910557 Amgen ID*: 20130193	Status		Phase 4
Postmarketing Prospective Study of Melanoma Patients Treated With Talimogene Laherparepvec to Characterize Risk of Herpetic Infection	Ⓡ		
NCT: 02173171 Amgen ID*: 20120139	Status		Enrolling by invitation only
Registry Study to Evaluate the Survival and Long-Term Safety of Patients With Melanoma Who Previously Received Talimogene Laherparepvec	Registry		

*For more detailed information about the trial, visit www.clinicaltrials.gov or www.amgentrials.com. [†]Sponsored by Onyx Pharmaceuticals, an Amgen subsidiary. [‡]The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification. ^{††}Previously referred to as OncoVEX^{GM-CSF}. ^{**}For detailed information on this study please visit <http://www.encepp.eu/encepp/studiesDatabase.jsp>. [#]AMG 506 (also known as MPO310) is being developed in collaboration with Molecular Partners AG. DARPin[®] is a registered trademark owned by Molecular Partners AG.

XmAb[®] is a registered trademark of Xencor.


ALL – acute lymphoblastic leukemia; AML – acute myelogenous leukemia; BiTE[®] – bispecific T cell engager; CD – cluster of differentiation; CLDN – claudin-1; CNS – central nervous system; DARPin[®] – designed ankyrin repeat proteins; DLBCL – diffuse large B-cell lymphoma; DLL3 – delta-like ligand 3; EGFR – epidermal growth factor receptor; EGFRvIII – epidermal growth factor receptor variant III; FAP – fibroblast activation protein; FLT-3 – fms-like tyrosine kinase 3; G-CSF – granulocyte colony-stimulating factor; HLE – half-life extended; INN – International Nonproprietary Name; ITP – immune thrombocytopenic purpura; IL-21 – interleukin-21, IV – intravenous; KRAS – Kirsten rat sarcoma 2 viral oncogene homolog; mAb – monoclonal antibody; mCRPC – metastatic castration-resistant prostate cancer; MCL-1 – myeloid cell leukemia sequence 1; MM – multiple myeloma; MUC – mucin; NHL – non-hodgkin lymphoma; PD-1 – programmed cell death protein-1; PD L1 – programmed death-ligand 1; PK – pharmacokinetics; PNH – paroxysmal nocturnal hemoglobinuria; PSMA – prostate-specific membrane antigen; RANK – receptor activator of nuclear factor kappa B; RR – relapsed or refractory. SCLC – small cell lung cancer; STEAP – six-transmembrane epithelial antigen of the prostate.

Information as of July 10, 2020. Statements are based on the company's current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen's filings with the SEC. Products under investigational study have not been approved by regulatory agencies for the use under investigation. This information is provided only for purposes of providing general information on clinical trials and stages of development on the select candidates identified. This information should not be construed as a recommendation for use of any product for unapproved uses.

Ⓝ Not yet recruiting Ⓡ Active, recruiting Ⓐ Active, not recruiting Ⓝ Completed, pending results

MODALITIES

Amgen has built an array of drug modalities that is unsurpassed in the biopharma industry.



INSIDE BACK COVER

Amgen's Research and Development Guiding Principles

Amgen aspires to be the best human therapeutics company. Achieving this goal starts with building the world's premier R&D organization. Amgen's R&D Guiding Principles were inspired by this pursuit and designed to reinforce our strategic priorities.

Focus on innovative medicines for unmet needs in patients with serious illnesses. While Amgen is always pursuing new opportunities and adapting to challenges, we retain an enduring commitment to the same mission. That mission is to enhance and extend the lives of patients facing serious illness.

Pursue targets that are validated in humans. We believe we are on the threshold of a revolution in science in which population genetics will help to reveal new targets that clearly drive disease risk in humans. By focusing on targets supported by human genetics or other strong human evidence, we aim to increase our clinical success rates, reduce development timelines, and lower the cost of delivering new medicines to patients.

Maintain multiple drug modalities with a focus on biologics. Amgen pursues a "biology-first" approach to drug discovery. We strive to select drug targets based on a deep understanding of disease biology, and then choose the drug modality, or structural template, best suited to the target. We recognize our strength in biologics and the higher clinical success rates for biologic medicines. We also maintain a broad toolkit of modalities, including small molecules, in order to have the right tool for any target we pursue.

Focus on return on investment and operational efficiency. To maximize the value of Amgen's R&D investment, we focus resources on programs that offer a large effect size and more likelihood of success. We maximize the value of lower-priority assets by partnering and out-licensing. Amgen also strives to continually identify operational efficiencies, such as reduced cycle times, leaner clinical trials, and centralized monitoring of clinical study sites.

Harness external innovation. At Amgen, we pursue great innovation wherever we can find it, and roughly half of our current late-stage pipeline comes from collaborations or acquisitions. We appreciate the synergy between in-house and external innovation: To identify and add value to the best external inventions, we need to maintain a high level of in-house scientific talent and capabilities.

Demonstrate the value of our medicines. Patients will not benefit from medicines they cannot access, and increasingly, access depends on meeting evolving standards from regulators and payers. To meet these expectations, we strive to deliver major therapeutic advances—medicines that offer compelling benefits for patients and sound health economics for society.